{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:08:25Z","timestamp":1740146905803,"version":"3.37.3"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"crossref","award":["RD12\/0036\/0060"],"award-info":[{"award-number":["RD12\/0036\/0060"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"crossref","award":["PI14\/00221"],"award-info":[{"award-number":["PI14\/00221"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"crossref","award":["PIE14\/0064"],"award-info":[{"award-number":["PIE14\/0064"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"crossref","award":["PI17\/00272"],"award-info":[{"award-number":["PI17\/00272"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"crossref","award":["CB16\/12\/00291"],"award-info":[{"award-number":["CB16\/12\/00291"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"crossref","award":["CB16\/12\/00291"],"award-info":[{"award-number":["CB16\/12\/00291"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"crossref","award":["CB16\/12\/00233"],"award-info":[{"award-number":["CB16\/12\/00233"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["B2017\/BMD3778"],"award-info":[{"award-number":["B2017\/BMD3778"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n de la Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer"},{"name":"Roche Farma SA"},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"crossref","award":["IFI14\/00003"],"award-info":[{"award-number":["IFI14\/00003"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"crossref","award":["CPII16\/00024"],"award-info":[{"award-number":["CPII16\/00024"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundaci\u00f3n de Investigaci\u00f3n Biom\u00e9dica Puerta de Hierro"},{"name":"Fundaci\u00f3n de Investigaci\u00f3n Biom\u00e9dica Puerta de Hierro"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in recent years by next-generation sequencing. These studies have identified recurrent somatic mutations in <jats:italic>NOTCH1<\/jats:italic>, <jats:italic>SF3B1<\/jats:italic>, <jats:italic>ATM<\/jats:italic>, <jats:italic>TP53<\/jats:italic>, <jats:italic>BIRC3<\/jats:italic> and others genes that play roles in cell cycle, DNA repair, RNA metabolism and splicing. In this study, we have taken a deep-targeted massive sequencing approach to analyze the impact of mutations in the most frequently mutated genes in patients with CLL enrolled in the REM (<jats:italic>rituximab en mantenimiento<\/jats:italic>) clinical trial. The mutational status of our patients with CLL, except for the <jats:italic>TP53<\/jats:italic> gene, does not seem to affect the good results obtained with maintenance therapy with rituximab after front-line FCR treatment.<\/jats:p>","DOI":"10.1371\/journal.pone.0257353","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T17:43:10Z","timestamp":1631295790000},"page":"e0257353","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)"],"prefix":"10.1371","volume":"16","author":[{"given":"Julia","family":"Gonz\u00e1lez-Rinc\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Garcia-Vela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagrario","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Fern\u00e1ndez-Cuevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Nova-Gurumeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"P\u00e9rez-Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-4846","authenticated-orcid":true,"given":"Miguel","family":"Alcoceba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Anguita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"L\u00f3pez-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Gonz\u00e1lez-Barca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9925-3048","authenticated-orcid":true,"given":"Lucrecia","family":"Y\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"P\u00e9rez-Persona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3904-1101","authenticated-orcid":true,"given":"Javier","family":"de la Serna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Fern\u00e1ndez-Zarzoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Deben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Pe\u00f1alver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda C.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-2037","authenticated-orcid":true,"given":"Jaime P\u00e9rez","family":"de Oteyza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. \u00c1ngeles","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. \u00c1ngeles","family":"Ru\u00edz-Guinaldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Paz-Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Dolores","family":"Garc\u00eda-Malo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5129-8597","authenticated-orcid":true,"given":"Valle","family":"Recasens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Collado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Navarro-Matilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-7599","authenticated-orcid":true,"given":"Margarita","family":"S\u00e1nchez-Beato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Garc\u00eda-Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"issue":"6","key":"pone.0257353.ref001","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"TJ Hamblin","year":"1999","journal-title":"Blood"},{"issue":"2","key":"pone.0257353.ref002","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/leu.2017.311","article-title":"Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups","volume":"32","author":"A Burns","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"pone.0257353.ref003","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"A Rosenwald","year":"2001","journal-title":"J Exp Med"},{"issue":"17","key":"pone.0257353.ref004","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"F Nadeu","year":"2016","journal-title":"Blood"},{"issue":"4","key":"pone.0257353.ref005","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood-2015-02-585042","article-title":"Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia","volume":"126","author":"R Gui\u00e8ze","year":"2015","journal-title":"Blood"},{"issue":"8","key":"pone.0257353.ref006","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2015-10-674572","article-title":"Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations","volume":"127","author":"V Ljungstr\u00f6m","year":"2016","journal-title":"Blood"},{"issue":"18","key":"pone.0257353.ref007","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1182\/blood-2015-05-647578","article-title":"Presence of multiple recurrent mutations confers poor trial outcome of relapsed\/refractory CLL","volume":"126","author":"R Gui\u00e8ze","year":"2015","journal-title":"Blood"},{"issue":"3","key":"pone.0257353.ref008","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"PA Thompson","year":"2016","journal-title":"Blood"},{"issue":"2","key":"pone.0257353.ref009","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"K Fischer","year":"2016","journal-title":"Blood"},{"issue":"16","key":"pone.0257353.ref010","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"D Rossi","year":"2015","journal-title":"Blood"},{"issue":"23","key":"pone.0257353.ref011","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"K Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0257353.ref012","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"TD Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"34","key":"pone.0257353.ref013","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study","volume":"38","author":"AP Kater","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"pone.0257353.ref014","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"S B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"pone.0257353.ref015","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3324\/haematol.2018.204891","article-title":"High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance","volume":"104","author":"JA Garc\u00eda-Marco","year":"2019","journal-title":"Haematologica"},{"issue":"7","key":"pone.0257353.ref016","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/leu.2017.125","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations","volume":"31","author":"R Rosenquist","year":"2017","journal-title":"Leukemia"},{"issue":"7354","key":"pone.0257353.ref017","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"XS Puente","year":"2011","journal-title":"Nature"},{"issue":"4","key":"pone.0257353.ref018","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"DA Landau","year":"2013","journal-title":"Cell"},{"issue":"9","key":"pone.0257353.ref019","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/2159-8290.CD-14-0104","article-title":"Acquired initiating mutations in early hematopoietic cells of CLL patients","volume":"4","author":"F Damm","year":"2014","journal-title":"Cancer Discov"},{"issue":"7","key":"pone.0257353.ref020","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2013-03-488197","article-title":"NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG","volume":"122","author":"A Schnaiter","year":"2013","journal-title":"Blood"},{"issue":"26","key":"pone.0257353.ref021","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"L Wang","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0257353.ref022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"V Quesada","year":"2012","journal-title":"Nat Genet"},{"issue":"7","key":"pone.0257353.ref023","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"G Fabbri","year":"2011","journal-title":"J Exp Med"},{"issue":"6","key":"pone.0257353.ref024","doi-asserted-by":"crossref","first-page":"e38158","DOI":"10.1371\/journal.pone.0038158","article-title":"New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing","volume":"7","author":"E Dom\u00e9nech","year":"2012","journal-title":"PloS One"},{"issue":"9","key":"pone.0257353.ref025","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"D Rossi","year":"2012","journal-title":"J Exp Med"},{"issue":"12","key":"pone.0257353.ref026","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"D Rossi","year":"2012","journal-title":"Blood"},{"issue":"11","key":"pone.0257353.ref027","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.3324\/haematol.2015.132837","article-title":"Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma","volume":"100","author":"C P\u00e9rez","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"pone.0257353.ref028","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"JT Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"4","key":"pone.0257353.ref029","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.bjc.6601120","article-title":"Survival analysis Part III: multivariate data analysis\u2014choosing a model and assessing its adequacy and fit","volume":"89","author":"MJ Bradburn","year":"2003","journal-title":"Br J Cancer"},{"issue":"3","key":"pone.0257353.ref030","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/leu.2017.296","article-title":"NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-\u03baB pathways","volume":"32","author":"D Benedetti","year":"2018","journal-title":"Leukemia"},{"key":"pone.0257353.ref031","first-page":"1","article-title":"Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial","author":"SJ Blakemore","year":"2020","journal-title":"Leukemia"},{"issue":"21","key":"pone.0257353.ref032","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"S Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"7574","key":"pone.0257353.ref033","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"DA Landau","year":"2015","journal-title":"Nature"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0257353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T17:43:48Z","timestamp":1631295828000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0257353"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0257353","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,9,10]]}}}